Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

AGM Statement

20 Sep 2007 07:01

Angle PLC20 September 2007 For Immediate Release 20 September 2007 ANGLE plc ('ANGLE' or the 'Company') AGM Statement At the Annual General Meeting of ANGLE plc today, Hance Fullerton, retiringChairman, will make the following statement: "ANGLE has made a strong start to the year, continuing to trade in line with theexpectations for the year outlined at our Preliminary Results announcement on 5July. Solid progress has been made in both of our key operating divisions. Our Management services business is now trading profitably and is expected todeliver at least £0.4 million profit for the year. In addition to successfullyimplementing £1m of annualised cost savings, ANGLE has also secured asignificant new contract win with the Innovation Lincolnshire Outreach Programmewhich, as announced on 27 June, will generate £0.9m of revenue for the Companyover a 21 month period. The Group will continue to pursue further such contractsin order to drive revenue growth and broaden its exposure to a pipeline ofpotentially high-value IP opportunities. Solid progress has also been made within our Ventures division. Evidence ofsuccessful value creation has been demonstrated, as announced on 5 July, througha £4 million profit from the gain in fair value of portfolio company Geomerics.Furthermore, in line with our current strategy, operating costs in this divisionhave also been reduced by an estimated £1.3 million on an annualised basis. As previously announced, I am retiring following today's Annual General Meetingand Garth Selvey is succeeding me as non-executive Chairman. I would like tothank the Chief Executive, other directors and senior management for all theirsupport over the years. I look forward to hearing of ANGLE's success in thefuture." Andrew Newland, Chief Executive will add: "I would like to take this opportunity to thank Hance for all his hard work anddedication to ANGLE over the years. Under his stewardship, the Group hasdeveloped from a start-up business to an established leader in IPcommercialisation. We wish Hance all the best for a long and enjoyableretirement and sincerely thank him for his outstanding contribution to ANGLE." Enquiries: ANGLE plc Andrew Newland, Chief Executive 01483 295830Ian Griffiths, Finance Director Collin Stewart Europe Limited 020 7523 8350Mark Connelly Scott Harris 0207 653 0030Stephen Scott, James O'Shaughnessy, Harry Dee Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.